Sign in
CVKD Stock Price, Chart, Stats & News
Cadrenal Therapeutics, Inc. Common Stock
Save
Cadrenal Therapeutics, Inc. Common Stock (CVKD) does not currently pay a dividend.
3.89M
Market cap
–
Current P/E
–
Forward P/E
CVKD chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -351.93% |
ROE | -279.52% |
D/E | – |
Interest coverage ratio | – |
CVKD valuation
P/E | – |
P/S | – |
P/B | 3.73x |
P/CF | -0.86x |
P/FCF | -0.99x |
P/OCF | -0.86x |
PEG | -0.07x |
EV multiple | -1.07x |
About
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation.
Similar securities
Based on sector and market capitalization
Report issue